Personalizing evidence-based primary prevention with aspirin individualized risks and patient preference

Circulation: Cardiovascular Quality and Outcomes

Volumn 4, Issue 3, 2011, Pages 260-262

  Kent, David M ^a,b   Shah, Nilay D ^c  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Antiplatelet; Aspirin; Editorials; Medical decision making; Patient centered care; Primary prevention.

Indexed keywords

ACETYLSALICYLIC ACID;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EVIDENCE BASED MEDICINE; HEALTH CARE QUALITY; INFORMED CONSENT; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; STOMACH HEMORRHAGE; TREATMENT DURATION;

ASPIRIN; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; PATIENT PARTICIPATION; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 79959769160     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.111.961136     Document Type: Review

References (21)

1. Table of NNTsBandolier JournalApril 1, 1998http://www.medicine.ox.ac.uk/ bandolier/band50/b50-8.html Accessed March 23, 2011.
2. Kent DM, Hayward RA Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification JAMA 2007;298:1209-1212. (Pubitemid 47403108)
3. Ioannidis JP, Lau J The impact of high-risk patients on the results of clinical trials J Clin Epidemiol 1997;50:1089-1098. (Pubitemid 27477985)
4. Sussman JB, Vijan S, Choi H, Hayward R AIndividual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines Circ Cardiovasc Qual Outcomes 2011; 4:268-275.
5. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement Ann Intern Med 2009; 150:396-404.
6. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KAAHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases: American Heart Association Science Advisory and Coordinating Committee Circulation 2002;106:388-391.
7. ARIC CHD Risk CalculatorAtherosclerosis Risk in Communities Study 2011http://www.aricnews.net/riskcalc/html/RC1.htmlAccessed March 23, 2011.
8. Framingham Risk ScoreFramingham Heart Study 2011 http://hp2010.nhlbihin. net/atpiii/calculator.asp?usertype-profAccessed March 23, 2011.
9. Ridker PM, Buring JE, Rifai N, Cook NRReynold's Risk Score2011. http://www.reynoldsriskscore.org/Accessed March 23, 2011.
10. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, Christianson TJ, Mullan RJ, Smith SA Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial Arch Intern Med 2007;167:1076-1082. (Pubitemid 46835796)
11. Montori VM, Shah ND, Pencille LJ, Branda ME, Van Houten HK, Swiglo BA, Kesman RL, Tulledge-Scheitel SM, Jaeger TM, Johnson RE, Bartel GA, Melton LJ, Wermers RAUse of a decision aid to improve treatment decision in osteoporosis: the OSTEOPOROSIS CHOICE randomized trial Am J Med In press.
12. Ancker JS, Senathirajah Y, Kukafka R, Starren JB Design features of graphs in health risk communication: a systematic review. J Am Med Inform Assoc 2006;13:608-618. (Pubitemid 44649360)
13. Carling CL, Kristoffersen DT, Montori VM, Herrin J, Schünemann HJ, Treweek S, Akl EA, Oxman AD The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial PLoS Med 2009;6:e1000134.
14. Siegel CA, Levy LC, Mackenzie TA, Sands BEPatient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel diseaseInflamm Bowel Dis2008;14:1-6. (Pubitemid 351196861)
15. Habib SB, Sonoda L, See TC, Ell PJ, Groves AMHow do patients perceive the benefits and risks of peripheral angioplasty? Implications for informed consentJ Vasc Interv Radiol2008;19:177-181. (Pubitemid 351146638)
16. Ravdin PM, Siminoff IA, Harvey JA Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy J Clin Oncol 1998;16:515-521. (Pubitemid 28135593)
17. Meltzer D, Egleston B How patients with diabetes perceive their risk for major complications Eff Clin Pract 2000;3:7-15.
18. Rothberg MB, Sivalingam SK, Ashraf J, Visintainer P, Joelson J, Kleppel R, Vallurupalli N, Schweiger MJ Patients' and cardiologists' perceptions of the benefits of percutaneous coronary intervention for stable coronary disease Ann Intern Med 2010;153:307-313.
19. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM Percutaneous coronary interventions for nonacute coronary artery disease: a quantitative twenty-year synopsis. Lancet 2009;373:911-918.
20. Nannenga MR, Montori VM, Weymiller AJ, Smith SA, Christianson TJ, Bryant SC, Gafni A, Charles C, Mullan RJ, Jones LA, Bolona ER, Guyatt GH A treatment decision aid may increase patient trust in the diabetes specialist: the Statin Choice Randomized Trial. Health Expect 2009;12: 38-44.
21. Mullan RJ, Montori VM, Shah ND, Christianson TJ, Bryant SC, Guyatt GH, Perestelo-Perez LI, Stroebel RJ, Yawn BP, Yapuncich V, Breslin MA, Pencille L, Smith SAThe diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med 2009;169:1560-1568.